World's First! Visco Bio/Kawasaki University's vaccine against XBB and other new coronaviruses approved for emergency use by the state

On 8 June 2023, the recombinant trivalent neocoronavirus (XBB.1.5+BA.5+Delta variant) trimeric protein vaccine (Sf9 cells) developed by Wisker Biotech/Chuan Da Huaxi - Wikxin® 3-valent XBB vaccine was included in the emergency use with the approval of the relevant state departments, which is the world's first neocoronavirus vaccine approved for emergency use against the mutant strains of XBB and other mutants, marking that China's This is the first new crown vaccine approved for emergency use in the world against XBB and other mutant strains, signifying that China's R&D and innovation in new crown vaccines has been at the forefront of the world.

With state funding and strong support from various state ministries, provincial and municipal departments, Chengdu Visco Biomedical Co., Ltd. and its subsidiary Visco Biomedical (Guangzhou) Co., Ltd. have efficiently completed the recombinant trivalent neocoronavirus (XBB.1.5+BA.5+Delta mutant strain) trimeric protein We have efficiently completed the vector construction of recombinant trivalent XBB virus (XBB.1.5+BA.5+Delta variant) trimeric protein vaccine (Sf9 cells), and produced high purity and high quality recombinant trivalent protein vaccine. Vickersin® 3-valent XBB vaccine targets the spiny protein receptor binding domain (S-RBD) and heptapeptide repeat domain (HR) of the new crown mutant strain XBB and BA.5, etc. Based on the precise structural design of the subunit vaccine antigen, the vaccine was self-assembled into protein particles of stable trimeric structure, which were purified and mixed, and then made by adding the squalene-based oil-in-water emulsion adjuvant. The innovative adjuvant dramatically increased the neutralising antibody titre of the vaccine, enabling the trimeric protein vaccine to induce a stronger T-cell immune response in vivo. Clinical trial data showed that Vickersin® 3-valent XBB vaccine induced high levels of neutralising antibodies against variants XBB.1, XBB.1.5, XBB.1.16, XBB.1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75. Fourteen days after vaccination, the protection efficacy against symptomatic neocollagenic disease caused by infection with XBB.1, XBB.1.5 and XBB.1.9 mutant strains was 93.28%, and the safety was good, suggesting that the Vickersin® 3-valent XBB vaccine is a new generation of broad-spectrum neocollagenic vaccine targeting multiple mutant strains of XBB prevalent at home and abroad.

At the beginning of 2023, the XBB series of mutant strains gradually became the dominant epidemic strain of the new coronavirus in many places around the world. A team of scientists from Visco Biologics and West China Hospital of Sichuan University, taking advantage of their strengths in vaccine research and development, launched scientific and technological campaigns against the XBB series of mutant strains, and at the critical moment, they received the prospective and professional guidance and support from the State Council's Joint Prevention and Control Mechanism Scientific Research and Attack Group for vaccine R&D specialised in vaccine research and development.

At the press conference of the Joint Prevention and Control Mechanism of the State Council held on 8 May, experts from the Institute of Virus Research of the Chinese Academy of Disease Control introduced that "the XBB series of mutant strains, with its high transmission power and immune escape ability, is stronger than that of the Omicron mutant strains that were popular in the early days, and it has become the mainstream strain in the world at present." As of the end of May, in the United States, the XBB series of new coronavirus variants has accounted for 98.1 per cent. In China, newly detected XBB series strains accounted for a gradually increasing proportion of the variants of key concern, which has exceeded 90%. 18 May, the World Health Organization's (WHO) Technical Advisory Group on Composition of Neocoronavirus Vaccines (TAG-CO-VAC) made a recommendation for this year's Neocoronavirus Vaccine Composition Updates, which suggests that future vaccines should be targeted at the global mainstream Neocoronavirus strain, the XBB variant, to induce a neutralising antibody response. The future vaccine should induce a neutralising antibody response against the XBB variant of the dominant global neoguana strain.

Source: Vaccine Circle